7,300 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by Infrastructure Capital Advisors LLC

Infrastructure Capital Advisors LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 7,300 shares of the biopharmaceutical company’s stock, valued at approximately $491,000.

A number of other large investors also recently bought and sold shares of HALO. DLD Asset Management LP raised its holdings in Halozyme Therapeutics by 20.0% in the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Norges Bank acquired a new position in Halozyme Therapeutics in the 4th quarter worth about $128,201,000. William Blair Investment Management LLC acquired a new position in Halozyme Therapeutics in the 4th quarter worth about $124,031,000. Voloridge Investment Management LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth about $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new position in Halozyme Therapeutics in the 2nd quarter worth about $51,295,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $68.57 on Thursday. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The stock has a 50 day moving average of $67.86 and a two-hundred day moving average of $68.66. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The firm has a market cap of $8.13 billion, a P/E ratio of 24.67, a price-to-earnings-growth ratio of 0.29 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Morgan Stanley reduced their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares in the company, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total value of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $53,030,564.60. This trade represents a 1.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 93,250 shares of company stock valued at $6,299,746. 2.50% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.